Strategic combination therapy overcomes tyrosine kinase coactivation in adrenocortical carcinoma

Surgery (United States)

Volumn 152, Issue 6, 2012, Pages 1045-1050

  Lin, Chi Iou ^a   Whang, Edward E ^a   Moalem, Jacob ^b   Ruan, Daniel T ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CD135 ANTIGEN; CHECKPOINT KINASE 2; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; HEMATOPOIETIC CELL KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE YES; PROTEIN RET; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; SYNAPTOPHYSIN; VASCULOTROPIN RECEPTOR 2;

ADRENAL CORTEX CARCINOMA; ARTICLE; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; PRIORITY JOURNAL;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FLAVONOIDS; HUMANS; INDOLES; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PYRROLES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84869494061     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2012.08.035     Document Type: Article

References (12)

1. A.T. Phan Adrenal cortical carcinoma - review of current knowledge and treatment practices Hematol Oncol Clin North Am 21 2007 489 507 viii-ix
2. D.E. Schteingart, G.M. Doherty, and P.G. Gauger Management of patients with adrenal cancer: recommendations of an international consensus conference Endocr Relat Cancer 12 2005 667 680
3. R. Costa, R. Wesolowski, and D. Raghavan Chemotherapy for advanced adrenal cancer: improvement from a molecular approach? BJU Int 108 2011 1546 1554
4. H.G. Chun, A. Yagoda, N. Kemeny, and R.C. Watson Cisplatin for adrenal cortical carcinoma Cancer Treat Rep 67 1983 513 514
5. E. Baudin, C. Docao, and C. Gicquel Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma Ann Oncol 13 2002 1806 1809
6. J.O. Lee, K.W. Lee, and C.J. Kim Metastatic adrenocortical carcinoma treated with sunitinib: a case report Jpn J Clin Oncol 39 2009 183 185
7. J.M. Stommel, A.C. Kimmelman, and H. Ying Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies Science 318 2007 287 290
8. C.I. Lin, E.E. Whang, and M.A. Abramson Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells Biochem Biophys Res Commun 379 2009 626 631
9. T. Guo, M. Hajdu, and N.P. Agaram Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance Clin Cancer Res 15 2009 6862 6870
10. D. Huang, Y. Ding, and M. Zhou Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma Cancer Res 70 2010 1063 1071
11. K.J. Gotink, H.J. Broxterman, and M. Labots Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance Clin Cancer Res 17 2011 7337 7346
12. M. Kroiss, M. Quinkler, W.K. Lutz, B. Allolio, and M. Fassnacht Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma Clin Endocrinol (Oxf) 75 2011 585 591